Join our daily newsletter At The Bell to receive exclusive market insights
Firebrick Pharma (ASX:FRE) founder and CEO Peter Molloy addressed investors this week around commercialisation of Nasodine, a nasal spray that kills cold and flu viruses without any potential for resistance.
The product developed from PVP-iodine (the same active ingredient in the antiseptic brand Betadine) and is available to Australians online.
Firebrick is already establishing other markets in the US, Singapore, Fiji, South Pacific and the Philippines.
Dr Molloy – who launched Betadine in Australia – speaks about how the human mindset has changed in relation to viruses since COVID. He says there’s also widespread fear of future pandemics.
“We’re on a quest,” he says.
“We have a moral, ethical obligation to make Nasodine available worldwide.”
Firebrick Pharma is a pharmaceutical developer focused on developing and commercialising novel formulations and uses of povidone-iodine.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
